- Home
- SPOK vs FDMT Comparison
SPOK vs FDMT Comparison
Compare SPOK & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPOK
- FDMT
- Stock Information
- Founded
- SPOK 2004
- FDMT 2013
- Country
- SPOK United States
- FDMT United States
- Employees
- SPOK N/A
- FDMT N/A
- Industry
- SPOK Telecommunications Equipment
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- SPOK Telecommunications
- FDMT Health Care
- Exchange
- SPOK Nasdaq
- FDMT Nasdaq
- Market Cap
- SPOK 329.2M
- FDMT 268.6M
- IPO Year
- SPOK 1992
- FDMT 2020
- Fundamental
- Price
- SPOK $15.92
- FDMT $4.58
- Analyst Decision
- SPOK Hold
- FDMT Buy
- Analyst Count
- SPOK 1
- FDMT 11
- Target Price
- SPOK $15.00
- FDMT $41.70
- AVG Volume (30 Days)
- SPOK 98.5K
- FDMT 1.1M
- Earning Date
- SPOK 02-19-2025
- FDMT 02-27-2025
- Dividend Yield
- SPOK 7.86%
- FDMT N/A
- EPS Growth
- SPOK N/A
- FDMT N/A
- EPS
- SPOK 0.71
- FDMT N/A
- Revenue
- SPOK $137,714,000.00
- FDMT $17,000.00
- Revenue This Year
- SPOK $2.45
- FDMT N/A
- Revenue Next Year
- SPOK $0.80
- FDMT $159.49
- P/E Ratio
- SPOK $22.41
- FDMT N/A
- Revenue Growth
- SPOK N/A
- FDMT N/A
- 52 Week Low
- SPOK $13.24
- FDMT $4.50
- 52 Week High
- SPOK $18.14
- FDMT $36.25
- Technical
- Relative Strength Index (RSI)
- SPOK 47.46
- FDMT 30.88
- Support Level
- SPOK $15.32
- FDMT $4.68
- Resistance Level
- SPOK $16.25
- FDMT $5.15
- Average True Range (ATR)
- SPOK 0.30
- FDMT 0.43
- MACD
- SPOK 0.02
- FDMT -0.05
- Stochastic Oscillator
- SPOK 61.22
- FDMT 3.69
About SPOK Spok Holdings Inc.
Spok Holdings Inc is a provider of healthcare communications. It reports three market segments namely Healthcare, Government, and Large enterprise. The company provides paging services and software solutions in the United States and abroad. It provides services such as Value-Added Services, Advisory Services, Assessment Services and Adoption Services.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.